Latest stories on MAZE
Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage
InvestorsHub63 · neutralanalyst
Why is Maze Therapeutics stock climbing today?
Investing.com Markets50 · neutralgeneral
Maze Therapeutics initiated with a Buy at Citi
The Fly61 · neutralanalyst
The Surprise That Sent Vertex — And Its Chief Rival — Soaring
Investors.com73 · bullishproduct/pr
Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
Barron's73 · bullishproduct/pr
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
Yahoo Finance28 · bearishgeneral
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
The Motley Fool28 · bearishgeneral
Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seeking Alpha56 · neutralgeneral
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
GlobeNewswire56 · neutralgeneral
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
StockTitan55 · neutralgeneral
Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist
Seeking Alpha58 · neutralgeneral
Maze Therapeutics Strengthens Board with New Director Appointments
TipRanks55 · neutralgeneral
Maze Therapeutics, Inc. (MAZE) files 8-K
SEC 8-K50 · neutralgeneral
Maze Therapeutics Announces Appointments to Its Board of Directors
StockTitan55 · neutralgeneral
Maze Therapeutics, Inc. (MAZE) files 8-K
SEC 8-K50 · neutralgeneral
Maze Therapeutics reports Q2 EPS (76c), consensus (70c)
The Fly56 · neutralearnings
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
GlobeNewswire28 · bearishgeneral
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
StockTitan28 · bearishgeneral
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?
The Motley Fool42 · neutralgeneral
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor
TipRanks50 · neutralgeneral
Maze Therapeutics, Inc. (MAZE) files 8-K
SEC 8-K50 · neutralgeneral
Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha56 · neutralgeneral
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?
Yahoo Finance48 · neutralgeneral
Maze Therapeutics to Participate in Two Upcoming Investor Conferences | MAZE Stock News
StockTitan56 · neutralgeneral
Maze Therapeutics CFO Expands Role Amid Finance Leadership Change
TipRanks55 · neutralgeneral